Genomes and Genes
Affiliation: CHRU de Lille
- Phenotypic variability in ARCA2 and identification of a core ataxic phenotype with slow progressionCyril Mignot
Department of Genetics and Cytogenetics, AP HP, Hopital de la Salpetriere, Paris, F 75013, France
Orphanet J Rare Dis 8:173. 2013..e. low ubiquinone level or functional evidence of ubiquinone deficiency. This diagnosis is crucial since the neurological status of some patients may be improved by ubiquinone therapy...
- Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot studyCaroline Moreau
Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille, France
J Neurol Neurosurg Psychiatry 84:552-5. 2013..Given that memantine is thought to decrease N-methyl-D-aspartic-acid-related (NMDA) glutamatergic hyperactivity and improve locomotion in rats, we sought to assess the drug's impact on axial symptoms in advanced Parkinson's disease (PD)...
- Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's diseaseDavid Devos
INSERM French National Institute of Medical Research and Health, APHP Assistance Publique Hôpitaux de Paris, Clinical Investigation Center CIC 9503, Pitie Salpetriere Hospital, Paris, France Lille Nord de France University, Department of Medical Pharmacology, Lille University Medical Center, Faculty of Medicine of Lille 2, EA 4610, France Electronic address
Parkinsonism Relat Disord 20:170-5. 2014..In Parkinson's disease (PD), the response to L-dopa is highly variable and unpredictable. The major pathway for dopamine synthesis from L-dopa is decarboxylation by aromatic L-amino acid decarboxylase (AAAD, encoded by the DDC gene)...
- New pharmacological options for treating advanced Parkinson's diseaseDavid Devos
Department of Medical Pharmacology, EA 1046, Lille Nord de France University, Lille, France Electronic address
Clin Ther 35:1640-52. 2013..Fourthly, there is a need for disease- modifying treatments (DMTs) that slow disease progression and reduce the occurrence of the very disabling disorders seen in late-stage PD...
- Methylphenidate : a treatment for Parkinson's disease?David Devos
Department of Medical Pharmacology, EA 1046, Lille Nord de France University, CHU Lille, Lille, France
CNS Drugs 27:1-14. 2013..Pharmacogenetic tools could be of use in better defining study patients as a function of their dopaminergic metabolism and drug responsiveness...
- Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegiaSophie Tezenas du Montcel
Department of Biostatistics and Medical Informatics, and Pitié Salpêtrière Charles Foix Clinical Research Unit, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, Paris, France
Arch Neurol 69:500-8. 2012..To evaluate disease progression and determine validity of clinical tools for therapeutic trials...
- Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trialDavid Devos
Department of Medical Pharmacology, Lille University Hospital, Lille, France
J Neurol Neurosurg Psychiatry 85:668-74. 2014..We sought to establish whether rivastigmine's ability to inhibit acetyl- and butyrylcholinesterases could relieve the symptoms of apathy in dementia-free, non-depressed patients with advanced PD...
- Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled studyDavid Devos
Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France
Mov Disord 23:850-7. 2008..A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage...
- Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patientsMelissa Tir
Department of Neurology, Salengro Hospital, Lille University Medical Centre, Lille, France
Neurosurgery 61:297-304; discussion 304-5. 2007..The primary objective was to describe the clinical outcome in terms of efficacy and tolerance in STN-DBS patients. A secondary objective was to discuss presurgery clinical characteristics a posteriori as a function of outcome...
- Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trialCaroline Moreau
Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France
Lancet Neurol 11:589-96. 2012....
- Effect of intermittent theta-burst stimulation on akinesia and sensorimotor integration in patients with Parkinson's diseaseAdrian Degardin
Universite Lille Nord de France, EA 4559, CHRU de Lille, Hopital Roger Salengro, F 59037 Lille Cedex, France
Eur J Neurosci 36:2669-78. 2012..No changes in SAI and LAI were observed. Our data suggest that iTBS might improve both akinesia and sensory processing in patients with PD taking levodopa...
- Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxiasEllis Chan
Department of Biostatistics and Medical Informatics and Pitié Salpêtrière Charles Foix Clinical Research Unit, AP HP, Paris, France
Mov Disord 26:534-8. 2011..Responsive ataxia rating scales are essential for determining outcome measures in clinical trials...
- Spinocerebellar ataxia: a rational approach to aetiological diagnosisAdrian Degardin
Department of Neurology, EA 2683, IMPRT, IFR114, Universite Lille Nord de France, CHRU, Lille, France
Cerebellum 11:289-99. 2012..Ophthalmological examination was the most helpful physiological assessment...
- The pattern of attentional deficits in Parkinson's diseaseKathy Dujardin
Laboratoire de Neurosciences Fonctionnelles et Pathologies, EA 4559, University of Lille 2, Lille, France
Parkinsonism Relat Disord 19:300-5. 2013..We also sought to identify the main demographic and clinical characteristics associated with attention deficits in Parkinson's disease...
- Parkinson's disease dementia can be easily detected in routine clinical practiceKathy Dujardin
Universite Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France
Mov Disord 25:2769-76. 2010....
- Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's diseaseDavid Devos
Department of Neurology and Movement Disorders, EA2683, IMPRT, IFR 114, Faculty of Medicine Lille 2, University of Lille Nord de France, Lille University Hospital, Lille, France
Fundam Clin Pharmacol 24:407-21. 2010..The goal of this review is to develop the various pathophysiological hypotheses published to date, in order to underpin and justify ongoing fundamental research and clinical trials in this disease area...
- Neurodegeneration with brain iron accumulation: clinical, radiographic and genetic heterogeneity and corresponding therapeutic optionsFrederik Clement
Department of Neurology, Hopital Roger Salengro, Lille, France
Acta Neurol Belg 107:26-31. 2007..Neurodegeneration with brain iron accumulation (NBIA), formerly known as Hallervorden-Spatz syndrome, is a heterogeneous group of disorders with different treatment options...
- Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 geneDomitille Gras
AP HP, Service de Neuropediatrie, Hopital Trousseau, Paris, France
J Neurol Neurosurg Psychiatry 83:956-62. 2012..The aim of the study was to refine the movement disorders phenotype. We also studied disease course and response to therapy in a large series of genetically proven patients...
- Characteristics of apathy in Parkinson's diseaseKathy Dujardin
Neurology and Movement Disorders Unit, EA2683, Faculty of Medicine and Lille University Hospital, Lille, France
Mov Disord 22:778-84. 2007..Although the neurochemical substrate of apathy remains poorly characterized, the strong link between apathy and cognitive impairment observed in several studies suggests the participation of nondopaminergic circuits...
- Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's diseaseDavid Devos
Department of Neurology, EA2683 IFR114 IMPRT, Hopital R Salengro, CHU Lille, France
Mov Disord 24:993-1000. 2009..Technical problems were commonplace. Duodenal levodopa infusion seems to be an effective last-line therapy for motor complications in Parkinson's disease. Hence, technical improvements and earlier introduction should be considered...
- Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: a magnetic resonance imaging shape analysisNicolas Carriere
Service de Neurologie et Pathologie du Mouvement, Centre Hospitalier Regional Universitaire, Lille, France Université Lille Nord de France, EA 1046, Lille, France
Mov Disord 29:897-903. 2014..There were no significant intergroup differences in cortical thickness or fractional anisotropy. Dopa-resistant apathy in PD was associated with atrophy of the left nucleus accumbens and the dorsolateral head of the left caudate...
- Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's diseaseKathy Dujardin
Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, EA2683, Lille, France
J Neurol 253:1154-9. 2006....
- Deficit of sensorimotor integration in normal agingAdrian Degardin
Universite Lille Nord de France, CHRU de Lille, Neurophysiologie Clinique, Hopital Roger Salengro, F 59037 Lille Cedex, France
Neurosci Lett 498:208-12. 2011..Decreased sensorimotor performance with aging appears to be associated with a decrease in the influence of proprioceptive inputs on motor cortex excitability at longer intervals (probably via higher order cortical areas)...
- CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patientsCaroline Moreau
Service de Neurologie et Pathologie du Mouvement, Hopital Roger Salengro, CHRU, Lille, France
Amyotroph Lateral Scler 10:175-81. 2009..Our results suggest alteration of the HIF-1alpha-mediated response to hypoxia during sporadic ALS, whereas the NFK-B pathway seems early activated...
- Targeting chelatable iron as a therapeutic modality in Parkinson's diseaseDavid Devos
1 Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France
Antioxid Redox Signal 21:195-210. 2014..Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments...
- Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairmentSophie Tezenas du Montcel
AP HP, Department of Biostatistics and Medical Informatics, Pitié Salpêtrière Charles Foix Clinical Research Unit, University Pierre et Marie Curie, Paris, France
Brain 131:1352-61. 2008....
- Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hoursMarie Bodenant
Department of Neurology, University Hospital of Lille, Lille, France
Cerebrovasc Dis 30:148-56. 2010..Stroke outcomes are worse in patients admitted at nonworking hours (NWH), but whether this is also true in patients treated with intravenous (i.v.) thrombolysis has not been definitely proven...
- Thickening of peripapillar retinal fibers for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-SaguenayJeremy Desserre
Service d Exploration de la Vision et Neuro Ophtalmologie, Hopital Roger Salengro, Lille, France
Cerebellum 10:758-62. 2011..This ophthalmological consideration has avoided misdiagnosis and led to the description of new mutations in our cases...
- Spectrum of movement disorders associated with glutaric aciduria type 1: a study of 16 patientsCyril Gitiaux
Universite Paris Descartes, Service de Neurologie Pediatrique et Maladies Metaboliques, Hopital Necker Enfants Malades, AP HP, Paris, France
Mov Disord 23:2392-7. 2008..The types and outcome of movement disorders in this setting should be taken into consideration during rehabilitation and for patient selection and evaluation in therapeutic trials...
- Abnormal cortical mechanisms in voluntary muscle relaxation in de novo parkinsonian patientsEtienne Labyt
Department of Clinical Neurophysiology, R Salengro Hospital, Lille University Medical Center, Lille Cedex, France
J Clin Neurophysiol 22:192-203. 2005..The authors suggest that this may be due to anomalous activity in inhibitory motor cortical systems and impaired sensorimotor integration of afferent inputs from muscle and joint receptors...
- Relationship between oscillations in the basal ganglia and synchronization of cortical activityFrancois Cassim
Service de Neurophysiologie Clinique, Hopital Roger Salengro, CHRU de Lille, 59037 Lille Cedex, France
Epileptic Disord 4:S31-45. 2002..Studies of cortical reactivity related to planning of voluntary movement in parkinsonian patients provide evidence that it is possible to influence cortical reactivity through the basal ganglia system...
- Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 geneBernard Puech
Service d Exploration de la Vision et Neuro Ophtalmologie, Hopital Roger Salengro, CHRU de Lille, Lille Cedex, France
Ophthalmology 118:564-73. 2011..A 10-year ophthalmologic and neurologic follow-up of 5 patients allowed us to describe the disease's characteristics, early symptoms and progression, associated ocular signs, and retinal changes in carriers...